|
1
|
Sherman SI: Thyroid carcinoma. Lancet.
361:501–511. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gilliland FD, Hunt WC, Morris DM and Key
CR: Prognostic factors for thyroid carcinoma. A population-based
study of 15,698 cases from the Surveillance, Epidemiology and End
Results (SEER) program 1973–1991. Cancer. 79:564–573. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Podnos YD, Smith D, Wagman LD and
Ellenhorn JD: The implication of lymph node metastasis on survival
in patients with well-differentiated thyroid cancer. Am Surg.
71:731–734. 2005.
|
|
4
|
Lundgren Cl, Hall P, Dickman PW and
Zedenius J: Clinically significant prognostic factors for
differentiated thyroid carcinoma: a population-based, nested
case-control study. Cancer. 106:524–531. 2006. View Article : Google Scholar
|
|
5
|
Wada N, Suganuma N, Nakayama H, Masudo K,
Rino Y, Masuda M and Imada T: Microscopic regional lymph node
status in papillary thyroid carcinoma with and without
lymphadenopathy and its relation to outcomes. Langenbecks Arch
Surg. 392:417–422. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Myers JN, Greenberg JS, Mo V and Roberts
D: Extracapsular spread. A significant predictor of treatment
failure in patients with squamous cell carcinoma of the tongue.
Cancer. 92:3030–3036. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Allen CT, Law JH, Dunn GP and Uppaluri R:
Emerging insights into head and neck cancer metastasis. Head Neck.
35:1669–1678. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tian Y, Schreiber R and Kunzelmann K:
Anoctamins are a family of Ca2+-activated Cl−
channels. J Cell Sci. 125:4991–4998. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hartzell HC, Yu K, Xiao Q, Chien LT and Qu
Z: anoctamin/TMEM16 family members are Ca2+-activated
Cl− channels. J Physiol. 587:2127–2139. 2009. View Article : Google Scholar
|
|
10
|
Galindo BE and Vacquier VD: Phylogeny of
the TMEM16 protein family: Some members are overexpressed in
cancer. Int J Mol Med. 16:919–924. 2005.PubMed/NCBI
|
|
11
|
Liu F, Cao QH, Lu DJ, Luo B, Lu XF, Luo RC
and Wang XG: TMEM16a overexpression contributes to tumor invasion
and poor prognosis of human gastric cancer through TGF-β signaling.
Oncotarget. 6:11585–11599. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jacobsen KS, Zeeberg K, Sauter DR, Poulsen
KA, Hoffmann EK and Schwab A: The role of TMEM16A (ANO1) and
TMEM16F (ANO6) in cell migration. Pflugers Arch. 465:1753–1762.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bolduc V, Marlow G, Boycott KM, Saleki K,
Inoue H, Kroon J, Itakura M, Robitaille Y, Parent L, Baas F, et al:
Recessive mutations in the putative calcium-activated chloride
channel anoctamin 5 cause proximal LGMD2L and distal MMD3 muscular
dystrophies. Am J Hum Genet. 86:213–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Penttilä S1, Palmio J, Suominen T, Raheem
O, Evilä A, Muelas Gomez N, Tasca G, Waddell LB, Clarke NF, Barboi
A, et al: Eight new mutations and the expanding phenotype
variability in muscular dystrophy caused by ANO5. Neurology.
78:897–903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Magri F, Del Bo R, D'angelo MG, Sciacco M,
Gandossini S, Govoni A, Napoli L, Ciscato P, Fortunato F, Brighina
E, et al: Frequency and characterisation of anoctamin 5 mutations
in a cohort of Italian limb-girdle muscular dystrophy patients.
Neuromuscul Disord. 22:934–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wahbi K, Béhin A, Bécane HM, Leturcq F,
Cossée M, Laforêt P, Stojkovic T, Carlier P, Toussaint M, Gaxotte
V, et al: Dilated cardiomyopathy in patients with mutations in
anoctamin 5. Int J Cardiol. 168:76–79. 2013. View Article : Google Scholar
|
|
17
|
Marconi C, Brunamonti Binello P, Badiali
G, Caci E, Cusano R, Garibaldi J, Pippucci T, Merlini A, Marchetti
C, Rhoden KJ, et al: a novel missense mutation in ANO5/TMEM16E is
causative for gnathodiaphyseal dyplasia in a large Italian
pedigree. Eur J Hum Genet. 21:613–619. 2013. View Article : Google Scholar :
|
|
18
|
Lahoria R, Winder TL, Lui J, Al-Owain MA
and Milone M: Novel ANO5 homozygous microdeletion causing myalgia
and unprovoked rhabdomyolysis in an arabic man. Muscle Nerve.
50:610–613. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wen W, Liang W, Wu J, Kowolik CM, Buettner
R, Scuto A, Hsieh MY, Hong H, Brown CE, Forman SJ, et al: Targeting
JAK1/STAT3 signaling suppresses tumor progression and metastasis in
a peritoneal model of human ovarian cancer. Mol Cancer Ther.
13:3037–3048. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yadav A, Kumar B, Datta J, Teknos TN and
Kumar P: IL-6 promotes head and neck tumor metastasis by inducing
epithelialmesenchymal transition via the JAK-STAT3-SNAIL signaling
pathway. Mol Cancer Res. 9:1658–1667. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Subramanian A, Tamayo P, Mootha VK,
Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub
TR, Lander ES, et al: Gene set enrichment analysis: a
knowledge-based approach for interpreting genome-wide expression
profiles. Proc Natl Acad Sci USA. 102:15545–15550. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu BH, Chen H, Cai CM, Fang JZ, Wu CC,
Huang LY, Wang L and Han ZG: Epigenetic silencing of JMJD5 promotes
the proliferation of hepatocellular carcinoma cells by
downregulating the transcription of CDKN1a 686. Oncotarget.
7:6847–6863. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cho YA, Kong SY, Shin A, Lee J, Lee EK,
Lee YJ and Kim J: Biomarkers of thyroid function and autoimmunity
for predicting high-risk groups of thyroid cancer: a nested
case-control study. BMC Cancer. 14:873–883. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liang H, Liu M, Yan X, Zhou Y, Wang W,
Wang X, Fu Z, Wang N, Zhang S, Wang Y, et al: miR-193a-3p functions
as a tumor suppressor in lung cancer by downregulating ERBB4. J
Biol Chem. 290:926–940. 2015. View Article : Google Scholar
|
|
25
|
Kim HS, Kim DH, Kim JY, Jeoung NH, Lee IK,
Bong JG and Jung ED: Microarray analysis of papillary thyroid
cancers in Korean. Korean J Intern Med. 25:399–407. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu H, Pardoll D and Jove R: STATs in
cancer inflammation and immunity: a leading role for STAT3. Nat Rev
Cancer. 9:798–809. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
West RB, Corless CL, Chen X, Rubin BP,
Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R,
et al: The novel marker, DOG1, is expressed ubiquitously in
gastrointestinal stromal tumors irrespective of KIT or PDGFRa
mutation status. Am J Pathol. 165:107–113. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Carles A, Millon R, Cromer A, Ganguli G,
Lemaire F, Young J, Wasylyk C, Muller D, Schultz I, Rabouel Y, et
al: Head and neck squamous cell carcinoma transcriptome analysis by
comprehensive validated differential display. Oncogene.
25:1821–1831. 2006. View Article : Google Scholar
|
|
29
|
Liu W, Lu M, Liu B, Huang Y and Wang K:
Inhibition of Ca(2+)-activated Cl(−) channel aNO1/TMEM16A
expression suppresses tumor growth and invasiveness in human
prostate carcinoma. Cancer Lett. 326:41–51. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jia L, Liu W, Guan L, Lu M and Wang K:
Inhibition of calcium-activated chloride channel ANO1/TMEM16A
suppresses tumor growth and invasion in human lung cancer. PLoS
One. 10:e01365842015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sui Y, Sun M, Wu F, Yang L, Di W, Zhang G,
Zhong L, Ma Z, Zheng J, Fang X, et al: Inhibition of TMEM16A
expression suppresses growth and invasion in human colorectal
cancer cells. PLoS One. 9:e1154432014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Deng L, Yang J, Chen H, Ma B, Pan K, Su C,
Xu F and Zhang J: Knockdown of TMEM16A suppressed MAPK and
inhibited cell proliferation and migration in hepatocellular
carcinoma. Onco Targets Ther. 9:325–333. 2016.PubMed/NCBI
|
|
33
|
Shiwarski DJ, Shao C, Bill A, Kim J, Xiao
D, Bertrand CA, Seethala RS, Sano D, Myers JN, Ha P, et al: To
'grow' or 'go': TMEM16a expression as a switch between tumor growth
and metastasis in SCCHN. Clin Cancer Res. 20:4673–4688. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sauter DRP, Novak I, Pedersen SF, Larsen
EH and Hoffmann EK: ANO1 (TMEM16A) in pancreatic ductal
adenocarcinoma (PDAC). Pflugers Arch. 467:1495–1508. 2015.
View Article : Google Scholar :
|
|
35
|
Li Y, Wang X, Vural S, Mishra NK, Cowan KH
and Guda C: Exome analysis reveals differentially mutated gene
signatures of stage, grade and subtype in breast cancers. PLoS One.
10:e01193832015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Mohsenzadegan M, Shekarabi M, Madjd Z,
Asgari M, Abolhasani M, Tajik N and Farajollahi MM: Study of NGEP
expression pattern in cancerous tissues provides novel insights
into prognostic marker in prostate cancer. Biomarkers Med.
9:391–401. 2015. View Article : Google Scholar
|
|
37
|
Das S, Hahn Y, Walker DA, Nagata S,
Willingham MC, Peehl DM, Bera TK, Lee B and Pastan I: Topology of
NGEP, a prostate-specific cell:cell junction protein widely
expressed in many cancers of different grade level. Cancer Res.
68:6306–6312. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Duran C, Qu Z, Osunkoya AO, Cui Y and
Hartzell HC: ANOs 3–7 in the anoctamin/Tmem16 Cl−
channel family are intracellular proteins. Am J Physiol Cell
Physiol. 302:C482–C493. 2012. View Article : Google Scholar
|
